Industry struggling for business damage recovery caused by NHI policy changes on combined drugs.

The recent government reschedule policy for the combined non-prescription drugs gave an enormous business impact to the pharmaceutical industries and markets, bringing out about 165.9 BW of sales plummet for 742 products.

The top products to receive critical business damages thereby included Antacin (antacid), Anytal 3 layer tab. (a peptic ulcer drug), Cough syrup (a cough remedy), Deriborin...